OKYO Pharma Limited (OKYO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

OKYO Pharma Limited (OKYO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.04

0.01 (0.97%)

At close: Jan 14, 2025, 3:33 PM

1.09

5.19%

After-hours Jan 14, 2025, 05:42 PM EST

undefined% (undefined)

Bid	0.98
Market Cap	38.67M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.52
PE Ratio (ttm)	-2
Forward PE	n/a
Analyst	Buy

Ask	1.1
Volume	35,691
Avg. Volume (20D)	82,254
Open	1.03
Previous Close	1.03
Day's Range	1.01 - 1.10
52-Week Range	0.81 - 1.90
Beta	undefined

About OKYO

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incor...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 17, 2022

Employees 8

Stock Exchange NASDAQ

Ticker Symbol OKYO

Website https://www.okyopharma.com

Analyst Forecast

According to 1 analyst ratings, the average rating for OKYO stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 573.08% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

+19.42%

OKYO Pharma shares are trading higher after the co... Unlock content with Pro Subscription

4 months ago · Source

+14.72%

OKYO Pharma shares are trading higher after the company announced it secured a US Patent covering OK-101s potential to treat symptoms of dry eye disease.

News

2 months ago · proactiveinvestors.com

OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference

OKYO Pharma Ltd (NASDAQ:OKYO) announced it will present at the 10th International Tear Film & Ocular Surface Society (TFOS) Conference in Venice, Italy, being held from October 30 to November 2, 2024....

2 months ago · proactiveinvestors.com

OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMI

OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company's Phase 2 clinical trial for OK-101, an investigational therapy targeting neuropathic cornea...

2 months ago · proactiveinvestors.com

OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial

OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational therapeutic topical OK-101 to treat neuropathic corneal pain (NCP). NCP, which...

3 months ago · proactiveinvestors.com

OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment

OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at treating neuropathic corneal pain (NCP). The trial comes as part of OKYO's br...